Godavari Bioref.
Godavari Bioref. Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Godavari Biorefineries expects robust growth through capacity expansions, especially in grain/maize-based ethanol distilleries. Godavari Biorefineries aims to achieve a 3x EBITDA growth by FY29, targeting INR 3000 crores topline with 10-11% EBITDA margin (Page 13).
From Godavari Bioref.'s Q3 FY26 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Godavari Biorefineries expects robust growth through capacity expansions, especially in grain/maize-based ethanol distilleries.
- The company targets a significant increase in revenue, aiming for close to INR 3,000 crores topline by 2029 with 10-11% EBITDA margin.
- Expansion of bio-based chemicals, including specialty chemicals and bio-based monomers, is a key driver for high-margin growth.
- Increasing ethanol blending mandates (E20 achieved 5 years ahead of schedule) and potential introduction of flex fuel vehicles will boost ethanol demand.
- Continuous innovation and co-creation with customers to develop green transition products underpin growth.
- Consumer brand Jivana has crossed INR 100 crores sales in 9 months and is expected to broaden distribution and product portfolio.
- The company plans disciplined execution, capital efficiency, and portfolio optimization for sustainable long-term value creation.
Profitability & Margins
See what Godavari Bioref. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Godavari Biorefineries is investing in capacity expansion, notably:
- - Adding a grain-based (maize) ethanol distillery facility, with commissioning expected next quarter due to some equipment delays.
- - Continuing investments in bio-based specialty chemicals capacity through debottlenecking and expansions.
- Total planned capex is estimated at INR 325 crores by FY29, with approximately 75% allocated to bio-based chemicals and 25% to ethanol.
- Strategic investments include:
- - Licensing deal with Catalyxx for bio-based butanol production.
- - Collaboration with Synthomer to commercialize bio-based butyl acrylate.
- - Pilot plant development for dimethyl ether (DME) technology in partnership with the Institute of Chemical Technology.
- - Research into cancer biology molecules and bio-based chemical products as part of ongoing innovation pipelines.
- Focus on balancing capital allocation to ensure predictable earnings and managing feedstock and regulatory risks through multi-feedstock distilleries.
Fundraising & Capital Structure
See what Godavari Bioref. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention the current or expected order book or pending orders for Godavari Biorefineries Limited.
- The company has received binding supply obligations for ethanol volumes through OMC tenders for the ethanol supply year.
- Operational and financial preparations are underway to service these mandated volumes despite margin pressures from rising cane costs.
- The grain-based ethanol facility commissioning is delayed but expected by next quarter, which will support their capacity to meet orders.
- The company is focusing on adding capacity and debottlenecking in bio-based chemicals and ethanol to support growth.
- There is an active strategy to co-create specialized bio-based chemicals with customers, involving signed MOUs (e.g., with Synthomer for bio-based butanol), indicating ongoing and potential future orders in specialty chemicals.
- Overall, no specific numeric order book or pending orders data is disclosed.
Godavari Bioref. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹564 Cr, net profit ₹53 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Godavari Biorefineries Ltd's management said in earlier quarters
Others in Diversified FMCG this season
- Hindustan Foods Ltd (Q3 FY26)
Approximately INR 200 crores of capital is yet to be ramped up or underutilized, with additional capital work in progress (CWIP) and advances. Key concall…
- Hindustan Unilever Ltd (Q3 FY26)
The company is scaling its presence in fast-growing segments like Masstige and D2C channels, notably doubling down on brands like OZiva with full acquisition…
Frequently Asked Questions
What were Godavari Bioref. Q3 FY26 results?
Godavari Biorefineries expects robust growth through capacity expansions, especially in grain/maize-based ethanol distilleries. Godavari Biorefineries aims to achieve a 3x EBITDA growth by FY29, targeting INR 3000 crores topline with 10-11% EBITDA margin (Page 13).
What is Godavari Bioref. share price analysis?
Godavari Bioref. currently shows a neutral. The stock trades at a P/E of 43.6 with a market cap of ₹1,265 Cr. Investors should review the full earnings analysis for detailed insights.
Is Godavari Bioref. planning capital expenditure?
Godavari Biorefineries is investing in capacity expansion, notably: - Adding a grain-based (maize) ethanol distillery facility, with commissioning expected next quarter due to some equipment delays.
Keep Godavari Bioref. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.